Literature DB >> 16775722

Growth in post-viral chronic lung disease.

Mariana del Pino1, Gabriela Bauer, Hebe González Pena, Mario Grenoville, Horacio Lejarraga.   

Abstract

INTRODUCTION: Acute lower respiratory infection due to adenovirus is an important cause of chronic lung disease (CLD) in infants. The objectives of this paper is to describe growth in the height and weight of children with post-viral chronic lung disease (PVCLD) and to relate it with associated variables (invasive mechanical ventilation, chronic hypercapnia, oxygen therapy at home and steroid treatment).
MATERIALS AND METHODS: Ninety-nine patients with diagnosis of PVCLD with one or more years of follow-up were included in the study. The median duration of follow-up was 3.10 years. The median age at onset of the disease was 0.50 years.
RESULTS: According to the growth in height, there were 48 children with normal growth (Type A) and 50 with slow growth (Type B) followed by catch-up growth (N=45) or normal growth velocity (N=5); only one patient showed persistent slow growth. Chronic hypercapnia was a risk factor significantly associated to slow growth, with odds ratio, OR: 5.03; and 95% confidence interval, CI: 1.83/13.83. Patients with higher weight for height at the end of the slow-growth period showed greater gains in height during the following period (r=0.46).
CONCLUSION: Growth in children with PVCLD is heterogeneous but, in the majority of individual cases, it can be considered satisfactory. Chronic hypercapnia was associated with slow growth.

Entities:  

Mesh:

Year:  2006        PMID: 16775722     DOI: 10.1007/s00431-006-0179-z

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

Review 1.  Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia.

Authors:  S A Atkinson
Journal:  J Nutr       Date:  2001-03       Impact factor: 4.798

2.  Bronchopneumonia with serious sequelae in children with evidence of adenovirus type 21 infection.

Authors:  W R Lang; C W Howden; J Laws; J F Burton
Journal:  Br Med J       Date:  1969-01-11

3.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-10       Impact factor: 3.791

4.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-12       Impact factor: 3.791

5.  Adenovirus type 7h respiratory infections: a report of 29 cases of acute lower respiratory disease.

Authors:  P Murtagh; C Cerqueiro; A Halac; M Avila; A Kajon
Journal:  Acta Paediatr       Date:  1993 Jun-Jul       Impact factor: 2.299

6.  Molecular epidemiology of adenovirus acute lower respiratory infections of children in the south cone of South America (1991-1994).

Authors:  A E Kajon; A S Mistchenko; C Videla; M Hortal; G Wadell; L F Avendaño
Journal:  J Med Virol       Date:  1996-02       Impact factor: 2.327

7.  Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children.

Authors:  D M Becroft
Journal:  J Clin Pathol       Date:  1971-02       Impact factor: 3.411

8.  Molecular epidemiology of adenoviruses: global distribution of adenovirus 7 genome types.

Authors:  G Wadell; M K Cooney; A da Costa Linhares; L de Silva; M L Kennett; R Kono; R Gui-Fang; K Lindman; J P Nascimento; B D Schoub
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

Review 9.  Pathophysiology and treatment of bronchopulmonary dysplasia. Current issues.

Authors:  S H Abman; J R Groothius
Journal:  Pediatr Clin North Am       Date:  1994-04       Impact factor: 3.278

10.  Chronic lung damage caused by adenovirus type 7: a ten-year follow-up study.

Authors:  S Similä; O Linna; P Lanning; E Heikkinen; M Ala-Houhala
Journal:  Chest       Date:  1981-08       Impact factor: 9.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.